Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi populationArticle Published on 2022-08-292022-10-05 Journal: Scientific Reports [Category] SARS, 비임상, 임상, 진단, 치료기술, [키워드] age asthma patients AZD1222 clinical implication cohort study COVID-19 infection development dosage dropped effective vaccine Factors immune system immunization immunized immunoassay median NAb titer natural immunity neutralizing antibody persistence Prevent retained SARS-CoV-2 SARS-COV-2 infection Sex significant difference significantly study period subject subjects transmission of SARS-CoV-2 Vaccine was used [DOI] 10.1038/s41598-022-18302-9 [Article Type] Article
Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study중증 급성 호흡기 증후군 코로나 바이러스 2의 지속 기간 및 델타 변이에 대한 자연 면역 및 보호: 후향적 코호트 연구Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus Against Analysis Chain Reaction coronavirus coronavirus 2 COVID-19 defined Delta delta variant dominant Duration Effectiveness infected patient Infection initial natural natural immunity Patient PCR polymerase chain polymerase chain reaction positive positive PCR test Positive test Primary outcome protection Protective protective effectiveness Reinfection respiratory retrospective cohort study SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown subsequent symptomatic disease tested vaccination Vaccinations Vaccine [DOI] 10.1093/cid/ciab999 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022Article Published on 2022-08-012022-11-15 Journal: Eurosurveillance [Category] SARS, 변종, 진단, [키워드] 95% confidence interval adjusted odds ratio anti-N antibodies anti-N antibody anti-S antibody Anti-spike antibody COVID-19 COVID-19 cases COVID-19 vaccine hybrid Immunity incidence natural immunity omicron Omicron variant risk of COVID-19 SARS-CoV-2 sero-epidemiological survey. Seroprevalence Spain [DOI] 10.2807/1560-7917.ES.2022.27.33.2200619 PMC 바로가기
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya케냐 코로나19 예방접종의 역학적 영향 및 비용 효율성 분석Article Published on 2022-08-012022-09-11 Journal: BMJ Global Health [Category] SARS, 변종, [키워드] analyses Analysis assumed conducted Cost-effectiveness analysis Coverage COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines death dose epidemiological Epidemiology Frame health economics Immune escape Increasing introduced Kenya natural immunity Perspective Rapid reduced SARS-COV-2 infection slow target threshold Time frame Transmission model vaccination Vaccine Vaccines variant [DOI] 10.1136/bmjgh-2022-009430 PMC 바로가기 [Article Type] Article
Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution DynamicsRBD 오미크론 돌연변이 및 SARS-CoV-2 진화 역학과 관련된 면역 탈출Review Published on 2022-07-222022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, [키워드] absence Affect appearance bioinformatics COVID-19 COVID-19 pandemic described Dynamics escape Evolution explained Features Genome high affinity high mutation rate Host immune Immune escape Lineage Mutation mutation rate natural immunity omicron pathogenicity Protein RBD RBD mutations receptor SARS-CoV-2 SARS-CoV-2 evolution SARS-CoV-2 strains serotype Spike protein the Spike therapeutic therapeutic agent therapeutic agents Transmissibility Vaccine Vaccine development variant virus [DOI] 10.3390/v14081603 PMC 바로가기 [Article Type] Review
Cancer vaccines: Building a bridge over troubled watersReview article Published on 2022-07-132022-10-05 Journal: Cell [Category] 비임상, [키워드] Antigen approaches building Cancer Cancer cells help highlight immune system Mouse models natural immunity post-vaccination responses recent single-cell unique Vaccine [DOI] 10.1016/j.cell.2022.06.035 [Article Type] Review article
A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune ResponsesSARS-CoV2 자연 및 백신 유도 면역 반응의 상호 보완적 연합Review Published on 2022-07-132022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] benefit booster contributed COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines death deaths effective immune immune imprinting immune response immune responses Immunity individual induced infected individuals Infection less maintain natural natural immunity Neutralizing neutralizing antibody omicron pandemic progressed Protective protective role reducing Reinfection response risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 union vaccination Vaccine Vaccines variant [DOI] 10.3389/fimmu.2022.914167 PMC 바로가기 [Article Type] Review
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections증상이 있는 오미크론 감염에 대한 이전 감염 및 예방 접종의 영향Article Published on 2022-07-072022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis B.1.1.529 BNT162b2 booster vaccination case-control study conducted coronavirus coronavirus disease Coronavirus disease 2019 Critical dose Effect Effectiveness evaluate hybrid Immunity Infection Moderna mRNA mRNA-1273 National natural immunity of BNT162b2 omicron Pfizer-BioNTech resulting SARS-CoV-2 second dose symptomatic vaccination variant variants [DOI] 10.1056/NEJMoa2203965 PMC 바로가기 [Article Type] Article
Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Region’s Population델타(B.1.617.2)와 오미크론(B.1.1.529) SARS-CoV-2 변이체의 면역학적 회피 차이: 베네토 지역 인구에 대한 후향적 연구Article Published on 2022-07-042022-09-11 Journal: International Journal of Environmental Research an [Category] COVID19(2023년), SARS, 변종, [키워드] active immunization addition Affect B.1.1.529 B.1.617.2 booster vaccination Coverage Delta difference dose effective Effectiveness Factor form immunization immunological immunological evasion immunological protection incidence rate infected individual Infection Italy less minor multivariable natural immunity offer offered omicron Omicron variant performed Population receiving regimen Region Reinfection Retrospective study SARS-CoV-2 SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 infections survival analysis the SARS-CoV-2 the vaccine Vaccines variant variants Veneto Veneto region viral variant VOCs [DOI] 10.3390/ijerph19138179 PMC 바로가기 [Article Type] Article